Novo Nordisk has suggested that it’s going to discontinue the Protaphane InnoLet human insulin (rys) 100 IU/mL injection multidose cartridge on February 1, 2025. The gadget is used significantly among the many aged as a result of it’s simple to make use of and girls with gestational diabetes mellitus.
Novo Nordisk is advising folks to substitute Protaphane Penfill human insulin 100 IU/mL (ARTG 169635) or Humulin NPH biosynthetic human isophane insulin 100 IU/mL injection multidose cartridge (ARTG 39662).
Between now and February 1, the Therapeutic Items Administration is advising pharmacists to make use of a Severe Shortage Substitution Instrument (SSSI) to dispense the Protaphane Penfill human insulin (rys) 100 IU/mL injection multidose cartridge with out the necessity for a brand new prescription. These penfills will want a brand new insulin supply gadget and people utilizing it might want to know tips on how to insert cartridges and use the brand new pen safely and precisely.
Folks residing with diabetes who shall be affected by the discontinuation are suggested to ask their well being professionals about altering over to the urged replacements as quickly as potential.
Diabetes Australia has raised issues concerning the discontinuation, together with entry to the alternative gadget.
Whereas data for pharmacists and healthcare professionals has now been launched concerning the alternative, not all prescribers and pharmacists will see this data in a well timed method. Issues have additionally been raised about the price of the additional time or appointments that folks residing with diabetes might have with their GPs, educators or endocrinologists to acquire new scripts or gadget directions.
Diabetes Australia is looking for assurances that there shall be sufficient alternative gadgets out there when required; that there shall be no value to folks residing with diabetes; and that the substitute gadgets shall be out there throughout Australia together with in regional, rural, and Aboriginal and Torres Strait Islander communities.
Diabetes Australia will proceed its advocacy on behalf of the estimated 30,000 folks utilizing Innolet and replace the neighborhood as data turns into out there.
Additional data is out there from the Therapeutic Items Administration web site.
